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Abstract: The incidence and prevalence of dyspnea increases with age. Frequently, for the general practitioner with his 
limited diagnostic facilities, it is impossible to separate dyspnea from cardiac causes and non-cardiac causes. Without 
cardiac imaging it is also impossible to separate systolic dysfunction from diastolic dysfunction. After a thorough physical 
examination, initial screening of systolic and diastolic heart failure can be done by measurement of plasma NT-pro BNP 
or plasma BNP. Additionally a Chest X-Ray or ECG can be performed. To improve diagnostic performance an open 
access echocardiographic service can be initiated. Recent studies showed, that open access echocardiography can easily 
detect systolic and diastolic dysfunction in the community and can separate cardiac from non-cardiac dyspnea.  
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EPIDEMIOLOGY 
  Heart Failure has become a main cardiac problem in the 
modern western society with a prevalence of 2-6% of the 
population or five million cases in the United States [1,2]. 
The calculated lifetime risk of developing heart failure in the 
Framingham Heart Study is about 20% [3]. Nearly half of 
the patients with heart failure have a preserved ejection 
fraction [4,5] . While death from coronary artery disease and 
stoke has been decreasing , there has been an increase in the 
prevalence, morbidity and mortality from congestive heart 
failure [6]. The prognosis of advanced heart failure is poor. 
Half of the patients with mild to moderate heart failure die 
within five years and half of the patients with severe heart 
failure die within two years [7]. Sudden death accounts for 
half of these deaths and is 6-9 times more common than in 
the general population. Also patients with preserved ejection 
fraction have a high all cause mortality: a 22 to 29% one 
year mortality and a 65% five year mortality [5]. Apart from 
this, heart failure is a common reason for hospitalisation and 
is a large expense for insurance companies. One third of the 
these costs are made in out-patient care and two thirds are 
spent in the hospital setting [8]. To prevent deterioration of 
cardiac function, it is important that systolic and diastolic 
dysfunction are diagnosed in an early stage. Unfortunately, 
heart failure is a complex clinical syndrome, which roughly 
can be grouped in predominant abnormalities of systolic 
function and in predominant abnormalities of diastolic 
function. Distiction between systolic dysfunction and 
diastolic dysfunction is complicated by the fact, that diastolic 
dysfunction nearly always coexists with systolic dysfunction. 
Therefore, heart failure is frequently misdiagnosed and the 
validity of the diagnosis in primary care is poor [9].  
DEFINITION OF DIASTOLIC HEART FAILURE 
  The term diastolic heart failure is used to describe group 
of patients with the clinical signs of congestive heart failure  
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and normal diastolic volume and predominant abnormalities 
of in relaxation and increased passive stiffness [10,11]. 
There is slow and incomplete isovolumic pressure decline, 
slow and decreased early diastolic filling rate and volume 
and compensatory increased late diastolic filling by atrial 
contraction. In pure diastolic heart failure systolic left 
ventricular function is normal. The pathophysiological 
mechanism refers to the inability of the myofibrils to rapidly 
or completely return to their resting length. In this situation, 
the left ventricle cannot accept blood at low pressures and 
ventricular filling is slow or incomplete unless atrial pressure 
rises. With pressure-volume loops, diastolic dysfunction is 
characterized by increased left ventricular chamber stiffness 
(left and upward shift) of the diastolic pressure- volume 
relationship, which is the gold standard for determining 
diastolic heart failure (Fig. 1). 
 
Fig. (1). Diagram of diastolic left ventricular pressure-volume loop 
in a normal individual (interrupted line) and a patient with diastolic 
dysfunction (un-interrupted line) Note, that the end-diastolic and 
endsystolic volume is normal and that left ventricular ejection 
fraction is equal. However, the filling pressures in the patient with 
diastolic dysfunction is higher.  Detection of Systolic and Diastolic Heart Failure  Current Cardiology Reviews, 2009, Vol. 5, No. 2    113 
CLINICAL MANIFESTATION AND PHYSICAL 
EXAMINATION 
  The main approach to the patient with dyspnea is based 
on the history, physical examination, chest x-ray, and a 
series of laboratory diagnostic tests to establish the 
diagnosis, determine the etiology, and assess severity of 
heart failure. According to the Framingham data [12], heart 
failure can be diagnosed according to predefined clinical 
criteria: These criteria can be separated in major and minor 
clinical criteria. Major criteria are: Paroxysmal nocturnal 
dyspnea, orthopnea, elevated jugular venous pressure, 
pulmonary rales, third heart sound, cardiomegaly on chest x-
ray, pulmonary edema on chest x-ray, weight loss 4.5 kg in 
five days in response to treatment of presumed heart failure. 
The minor criteria are: bilateral leg edema, nocturnal cough, 
dyspnea on ordinary exertion, hepatomegaly, pleural 
effusion, tachycardia (heart rate 120 beats/min), weight loss 
4.5 kg in five days. The diagnosis of heart failure requires 
that 2 major or 1 major and 2 minor criteria cannot be 
attributed to another medical condition. Unfortunately, these 
symptoms are not specific and the clinical signs are not 
sensitive at all [13].  
  Severity of of symptomatic heart failure can be classified 
according to the criteria of the New York Heart Association, 
where: Class I indicate symptoms only at activity levels that 
would limit normal individuals Class II indicate symptoms 
with ordinary exertion Class III indicate symptoms with less 
than ordinary exertion and Class IV indicate at rest. 
  For a complete work-up of a heart failure patient, the 
initial evaluation includes the investigations in Table 1 [14]. 
Table  1.    ACC/AHA Guideline Summary: Initial Evaluation 
of Patients with Heart Failure 
Class I: There is evidence and/or general agreement that the initial 
evaluation of patients presenting with HF should include the following: 
1.  A complete history and physical examination to identify cardiac and 
noncardiac disorders or behaviors that might cause or accelerate the 
development or progression of HF.  
2.  A careful history of current and past use of alcohol, illicit drugs, 
standard or "alternative" therapies, and chemotherapy drugs.  
3.  An assessment of the ability to perform routine and desired activities 
of daily living.  
4.  An assessment of the volume status, orthostatic blood pressure 
changes, height and weight, and calculation of body mass index.  
5.  Laboratory studies including complete blood count, urinalysis, 
serum electrolytes (including calcium and magnesium), blood urea 
nitrogen, serum creatinine, fasting blood glucose (glycohemoglobin), 
lipid profile, liver function tests, and serum thyroid-stimulating 
hormone.  
6.  A twelve-lead electrocardiogram and chest radiograph 
(posteroanterior and lateral). 
7.  Two-dimensional echocardiography with Doppler to assess left 
ventricular ejection fraction (LVEF), left ventricular size, wall 
thickness, and valve function. Radionuclide ventriculography can be 
performed to assess LVEF and volumes.  
8.  Coronary arteriography if there is a history or angina or significant 
ischemia unless the patient is not eligible for revascularization of any 
kind.  
Class IIa: The weight of evidence or opinion is in favor of benefit from 
performing the following studies as part of the initial evaluation of patients 
presenting with HF:  
1.  Coronary arteriography in patients who have chest pain that may or 
may not be of cardiac origin who have not had a prior evaluation of 
their coronary anatomy and are eligible for coronary 
revascularization.  
2.  Coronary arteriography in patients with known or suspected 
coronary artery disease who do not have angina and are eligible for 
revascularization.  
3.  Noninvasive imaging to detect myocardial ischemia and viability in 
patients with known or suspected coronary artery who do not have 
angina and are eligible for revascularization.  
4.  When the contribution of HF to exercise limitation is uncertain, 
maximal exercise testing with or without measurement of respiratory 
gas exchange and/or blood oxygen saturation.  
5.  To identify candidates for cardiac transplantation or other advanced 
treatments, maximal exercise testing with measurement of 
respiratory gas exchange.  
6.  In selected patients, screening for hemochromatosis, sleep disturbed 
breathing, or human immunodeficiency virus (HIV) infection.  
7.  When suspected clinically, diagnostic tests for rheumatologic 
disease, amyloidosis, or pheochromocytoma. 
8.  Endomyocardial biopsy when a specific diagnosis is suspected that 
would influence therapy.  
9.  Measurement of serum B-type natriuretic peptide (BNP) in the 
urgent care setting if the clinical diagnosis of HF is uncertain.  
Class IIb: The weight of evidence or opinion is less well established for the 
following testing in the initial evaluation of patients with HF: 
1.  Noninvasive imaging to define the likelihood of coronary artery 
disease in patients with left ventricular dysfunction 
2.  Holter monitoring in patients who have a history of myocardial 
infarction and are being considered for electrophysiologic study to 
document the inducibility of ventricular tachycardia.  
Class III: There is evidence and/or general agreement that the following 
tests are not useful or may be harmful in the initial evaluation of patients 
with HF: 
1.  Routine endomyocardial biopsy in the absence of suspicion of a 
specific diagnosis that would influence therapy suspected.  
2.  Routine signal-averaged electrocardiography.  
3.  Routine measurement of serum neurohormones other than BNP (eg, 
norepinephrine or endothelin).  
 
BRAIN NATRIURETIC PEPTIDES 
  Natriuretic peptides are released in respond to increased 
intracardiac volume and pressure [15] and are secreted in the 
ventricle. The plasma concentrations of of these pepides are 
frequently elevated in patients with heart failure and 
asymptomatic cardiac dysfunction [16,17]. Concentrations of 
Brain Natriuretic Peptide and NT-Brain Natriuretic Peptide 
rise with increasing dyspnea complaints [18]. Although BNP 
does better than other clinical variables to detect or to rule 
out heart failure in patients with dyspnea at the emergency 
department [19], BNP is less accurate in the detection of 
asymptomatic left ventricular dysfunction [20]. In this group 
of patients, BNP is a valuable tool to be rule out heart failure 
[21].  
  The level of BNP in plasma may also reflect diastolic 
dysfunction as has been shown in several studies [22,23]. 
Elevated plasma levels of BNP can help to reinforce the 
diagnosis of diastolic dysfuncton in patients with a normal 
systolic function determined with any imaging technique. On 
the other hand can a low BNP level rule out diastolic 
dysfunction. One has to keep in mind, that BNP is not a 
stand alone diagnostic test and must be interpreted in a wider 
clinical context. Small increases are not specific for left 
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with right ventricular dysfunction and renal insufficiency 
[24,25]. Additionally one has to consider that the normal 
range of BNP is specific to age, sex and the used assay [26]. 
DIASTOLIC DYSFUNCTION 
  Diastolic heart failure is very common, especially in 
elderly women [27]. Patients with diastolic heart failure 
often have left venricular hypertrophy and relatively well 
preserved systolic function. Diastolic dysfunction is now 
more readily recognized and may account for more than half 
of the hospital admisions for heart failure [28]. Treatment of 
diastolic heart failure differs from the treatment of systolic 
heart failure [29].  
ECHO-DOPPLER IMAGING 
  Diastolic function can be measured with echo-Doppler 
imaging by interrogation of mitral inflow and pulmonary 
vein flow using pulsed-wave Doppler and tissue Doppler 
imaging of mitral annular motion. Using pulsed-wave 
Doppler at the mitral valve annulus, several parameters can 
be measured . Left ventricular isovolumic relaxation time 
(IVRT) is the time between aortic valve closure and mitral 
valve opening and represents dynamic left ventricular 
relaxation [30].
 Normal values are 65 ± 20 milliseconds [31].
 
The IVRT is prolonged (> 100 ms) in patients with diastolic 
dysfunction and normal filling pressures. IVRT is shortened 
if mitral valve opening occurs early, which can be seen in 
young adults and patients with increased mean left atrial 
pressure due to restrictive cardiomyopathy [32].  
  Pulsed Doppler interrogation of the mitral annular flow 
reveals a peak E wave and a peak A wave. The peak E wave 
measures the early diastolic transmitral pressure gradient and 
thus reflects the rapid filling phase. Normal values are 
between 70 and 100 cm/s. The peak A wave measures the 
late diastolic transmitral pressure gradient and thus 
represents atrial contraction. The normal value is 45 to 70 
cm/s. The overall characterization of left ventricular filling is 
by the E/A ratio, which normally is less than one See also 
Fig. (2). 
  Mitral deceleration time reflects left ventricular 
compliance in early diastole and is normally between 160 
and 220 msec. In normal young adults, there is a 
predominance of early diastolic filling (E wave) with only 
10% to 15% filling caused by atrial contraction. With the 
normal aging process, relaxation slows and causes reduced 
filling in early diastole and increased filling by atrial 
contraction [33].
  In patients with cardiac relaxation 
abnormalities, three abnormal filling patterns can be 
recognized. These filling patterns are known as impaired 
relaxation , pseudonormalization , and restrictive filling 
[34]. With a slight elevation of left atrial pressure from 8 to 
14 mm Hg, the E wave decreases and the A wave increases, 
resulting in an E/A ratio less than 1. The deceleration time is 
more than 240 msec.  
  A more severe compliance reduction and increase of left 
atrial pressure to 15 to 22 mm Hg results in a left ventricular 
filling pattern that appears normal but actually is not; this 
pattern is called a pseudonormal filling pattern. With this 
pattern, the E/A ratio is 1 to 1.5, and the deceleration time is 
normal. In more advanced disease, high atrial pressures (> 
22 mm Hg) cause blood to rapidly fill the slowly relaxing 
left ventricle in early diastole. A marked increase in early left 
ventricular diastolic pressure results in only limited 
additional filling. The pulsed wave (PW) flow pattern is now 
known to be restrictive with a high velocity of the E wave, 
an E/A ratio more than 2, and a short deceleration time of 
less than 160 msec. 
  Because transmitral flow patterns are load-sensitive, 
additional measurement of pulmonary vein flow is helpful is 
assessing left ventricular filling [35]. With experience, high-
quality PW Doppler transthoracic recordings can be obtained 
in 90% of patients.  
  The normal pulmonary vein flow shows a systolic flow 
(S) that is higher than the diastolic flow (D) with an atrial 
reversal flow (A). 
  Patients with impaired relaxation have a normal 
pulmonary vein flow pattern. Patients with 
pseudonormalization and restrictive filling have a decrease 
 
Fig. (2). Pulsed-wave doppler mitral flow velocity pattern showing different variables representative of diastolic function: peak E-wave 
velocity (E); Peak A-wave velocity (A); Ratio between E and A wave velocities; isovolumic relaxation time. Detection of Systolic and Diastolic Heart Failure  Current Cardiology Reviews, 2009, Vol. 5, No. 2    115 
of the S wave compared with the D wave and a pulmonary 
vein A wave flow reversal of > 35 cm/s.  
Tissue Doppler Imaging (TDI)  
  TDI is a new modality that measures the velocity of the 
myocardium during the cardiac cycle (i.e., diastolic function) 
instead of blood flow [35].
 TDI velocities can be displayed 
as spectral Doppler signals, color-encoded M-mode images, 
and two-dimensional color maps. Imaging is usually 
performed from the apical window. From this view, the axial 
motion of the ventricle is parallel to the transducer axis, and 
velocities are primarily related to left ventricular contraction 
and relaxation. The pulsed-wave sample volume is mostly 
placed within the septal and lateral regions of the mitral 
annulus. 
  Normally, a systolic part (Vs), an early diastolic part (Ve 
or E’), and a late diastolic part (Va or A’) can be 
differentiated. If diastolic function is normal, the peak of Ve 
tends to be earlier than the peak of the mitral flow E wave. 
Patients with impaired ventricular relaxation have a Ve/Va 
ratio less than 1 [36]. Tissue Doppler imaging seems to be 
less preload-dependent than mitral flow Doppler. The most 
robust index of diastolic function is the combination of 
pulsed wave Doppler of the mitral inflow in combination 
with tissue Doppler imaging. The ratio of early peak 
transmitral inflow velocity (E) to the tissue Doppler velocity 
of early diastolic myocardial ascent (E') is a reliable guide to 
elevated pulmonary capillary wedge pressure [37]. An E/E’ 
> 12 predicts an elevated wedge pressure, while a ratio < 8 
predicts a normal wedge pressure. 
SYSTOLIC DYSFUNCTION 
  Patients with systolic dysfunction present with left 
ventricular dilation and a reduced ejection fraction. Left 
ventricular damage from any cause can initiate and 
perpetuate a process called left ventricular remodeling. 
Ultimately this process culminates in an increase of left 
ventricular enddiastolic and endsystolic volumes, a reduced 
ejection fraction and an increase of left ventricular wall 
stress [38,39]. Heart failure is accompanied by changes in 
the cardiac myocyte and the interstitium [40].  
  Patients, who have dilated hearts and a reduced left 
ventricular ejection fraction may occasionally be 
asymptomatic and can be identified by echocardiographic 
population screening or screening of plasma brain natriuretic 
peptide [41,42].  
  Measurement with pressure-volume loops is the gold 
standard for assessment of left ventricular systolic 
dysfunction (Fig. 3). 
  In clinical practice, echocardiography is most frequently 
used technique for assessement of left ventricular systolic 
dysfunction.  
  With echocardiography, left ventricular systolic function 
can be assessed in several ways.  
  An echocardiographic examination can start with an M-
Mode with measurement of left ventricular internal 
dimensions in diastole and in systole. From these parameters 
fractional shortening and velocity of circumferential 
shortening can be calculated. An indirect of systolic 
dysfunction is the EPSS or E-point septal separation. 
Normally, the mitral valve E point is within 6 mm of the left 
side of the ventricular septum. In the presence of a decreased 
ejection fraction, this distance is increased. A patient with 
marked left ventricular dysfunction with an EPSS of 2.4 cm. 
The left ventricle is dilated and has a decreased fractional 
shortening. 
 
Fig. (3). Pressure-volume loops in a patient a normal individual 
(interrupted line) and a patient with systolic dysfunction (un-
interrupted line). Systolic dysfunction is characterised by decreased 
stoke work (the area inside the pressure-volume loop) and 
decreased ejection fraction. The slope of the endsystolic pressure-
volume relation is also decreased and moved downward and to the 
right [10].  
  Two dimensional echocardiography provides inherently 
superior spatial resolution for determining left ventricular 
size and function. Several methods have been developed for 
measurement of left ventricular volume and left ventricular 
ejection fraction. The most common method for determining 
ventricular volumes is the Simpson rule or the “rule of 
disks”. It requires recording of an apical four- or two 
chamber view from which the endocardial border is outlined 
in end-diastole and end-systole. The ventricle is then 
mathematically along its long axis into a series of disks of 
equal height. The individual disk volume is calculated as 
height x disk area, where height is assumed to be the total 
length of the left ventricular long axis divided by the number 
of segments or disks [43].  
  A more accurate technique to determine ventricular 
volume, especially in abnormally shaped ventricles, is with 
three dimensional echocardiography. The major technical 
limitation of three dimensional volume determination has 
been the cumbersome nature of reconstruction techniques 
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  Tissue Doppler Myocardial Imaging can be applied for 
the measurement of longitudinal systolic left ventricular wall 
motion. (Fig. 4). In patients with dilated cardiomyopathy, 
mitral annular systolic velocities are significantly lower 
compared to normals and correlate well with left ventricular 
ejection fraction [45]. Next to this Tissue Doppler Imaging is 
frequently used to quantify left ventricular asynchrony and 
the effects of biventricular pacing [46]. 
  Regional left ventricular function can be calculated with 
the myocardial velocity gradient or by strain rate imaging 
[47]. Strain is a change in length corrected for the original 
length or the fractional or percentage change from the 
original or unstressed dimension and reflects deformation of 
a structure. Strain rate is the rate of this deformation and is a 
strong index of left ventricular contractility.  
OPEN ACCESS ECHOCARDIOGRAPHY 
  As previously oulined, systolic or diastolic left 
ventricular dysfunction is difficult to identify solely on the 
basis of signs and symptoms [48]. The most easy may to 
have a correct diagnosis is by echocardiography. The last 
decade several projects in and outside the UK have been 
developed to make echocardiography directly available to 
general practitioners [27,49-52]. Open access echocardio-
graphy is defined as echocardiography requested by a 
general practitioner without prior clinical assessment by a 
cardiologist [53]. 
  The service has been very succesful in detecting left or 
right ventricular dysfunction and the etiology of cardiac 
murmurs. The echocardiogram frequently gives the general 
practitioner additional information with minor discomfort for 
the patient. The costs of setting up open access services can 
be considerable. Therefore there have been concerns about 
this service [53]. However, there have been no formal 
evaluations of the cost effectiveness of this service. Another 
possible disadvantage of an open access service could be 
overload of the department of echocardiography if strict 
criteria for referral are not taken. Unneccecary referrals can 
be avoided by take in account the rules as they have been 
described by the Britisch Working Group on open access 
echocardiography [52]. 
Table 2.  Open Access Echocardiograhy is Indicated in Patients 
with Dyspnea or Peripheral Edema if: 
•  Clinical assessment, ECG and other tests (BNP, Chest X-Ray) 
cannot eliminate cardiac disease as a cause. 
Cardiology referral should be considered if: 
•  Dyspnea and/or peripheral edema is accompanied by unequivocal 
signs of cardiac disease, or major ECG abnormalities, or major 
abnormalities of a chest X-Ray or an abnormal plasma BNP. 
Referral is not indicated in patients with dyspnea or peripheral edema, 
if: 
•  There are complete normal findings on cardiovascular assessment, a 
normal ECG, a normal plasma BNP or an alternative explanation for 
the signs and symptoms. 
 
  Until now the service is has gained only acceptance in 
the United Kingdom and the Netherlands. The service is 
cost-effective and can avoid unneccesary referrals to the 
outpatient clinic of cardiology. 
 
Fig. (4). Pulsed wave Doppler at the basal septum (Fig. 2). The first positive wave is the systolic wave (Vs) the first negative wave, the 
early diastolic wave (Ve) and the second negative wave the late diastolic wave (Va). Detection of Systolic and Diastolic Heart Failure  Current Cardiology Reviews, 2009, Vol. 5, No. 2    117 
  Another way to limit the number of referrals is by 
prescreening of patients by making electrocardiograms or by 
measurement of plasma BNP [54]. Because a normal 
electrocardiogram and a normal BNP excludes systolic or 
diastolic dysfunction, this process can limit the number of 
unneccessary referrals. 
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